Research Topics
| Marjorie GreenSummaryAffiliation: The University of Texas Country: USA Publications
| Collaborators
|
Detail Information
Publications
Neoadjuvant chemotherapy for operable breast cancerMarjorie Green
Department of Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston 77030 4009, USA
Oncology (Williston Park) 16:871-84, 889; discussion 889-90, 892-4, 897-8. 2002..Nonetheless, evidence from more recent phase III trials and the fact that neoadjuvant chemotherapy is not harmful topatients validate its use in operable breast cancer...- Adjuvant chemotherapy for breast cancerMarjorie C Green
Department of Breast Medical Oncology, MD Anderson Cancer Center, University of Texas, TX 77030 4009, USA
Langenbecks Arch Surg 387:109-116. 2002..This article review the background and implementation of the current use of chemotherapy in adjuvant setting... - Neoadjuvant chemotherapyMarjorie C Green
Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
Breast Dis 21:23-31. 2004 - Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeksMarjorie C Green
The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 424, Houston, TX 77030, USA
J Clin Oncol 23:5983-92. 2005.... - Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of responseRadhika Rajan
Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030-4009, USA
Cancer 100:1365-73. 2004.... - Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancerCornelia Liedtke
Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 1439, USA
J Clin Oncol 26:1275-81. 2008..In this study, we compared response to neoadjuvant chemotherapy and survival between patients with TNBC and non-TNBC... - Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapyW Fraser Symmans
Department of Pathology, Unit 85, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
J Clin Oncol 25:4414-22. 2007..To measure residual disease after neoadjuvant chemotherapy in order to improve the prognostic information that can be obtained from evaluating pathologic response... - Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancerRoman Rouzier
Department of Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
Proc Natl Acad Sci U S A 102:8315-20. 2005..Low tau expression may be used as a marker to select patients for paclitaxel therapy. Inhibition of tau function might be exploited as a therapeutic strategy to increase sensitivity to paclitaxel... - Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancerBanu Arun
Department of Breast Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
Cancer Prev Res (Phila) 5:276-82. 2012..Anastrozole is currently being studied as a prevention agent in a large phase III trial and our results provide support for continued evaluation of IGFBP-1 as a surrogate endpoint biomarker in prospective breast chemoprevention studies... - Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trialsBanu Arun
Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 13:4943-8. 2007..The optimum method to retrieve adequate samples and the most accepted method by study participants is not known... - Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapyFlorentia Peintinger
Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Ann Surg Oncol 13:1443-9. 2006..Agreement of residual tumor size in mammography and sonography with pathologic residual tumor size was moderate... - Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized studyAman U Buzdar
Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 13:228-33. 2007..All data were updated through November 2005... - Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancerAman U Buzdar
Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 424, Houston, TX 77030, USA
J Clin Oncol 23:3676-85. 2005.... - Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinomaW Fraser Symmans
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 97:2960-71. 2003..This study compared gene expression profiles derived from fine-needle aspiration biopsy (FNAB) and from core needle biopsy (CBX)... - Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomesShaheenah Dawood
Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
J Clin Oncol 27:220-6. 2009..The goal of this study was to describe the effect of race on pathologic complete response (pCR) rates and survival outcomes in women with triple receptor-negative (TN) breast cancers... - Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancersGiampaolo Bianchini
Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
J Clin Oncol 28:4316-23. 2010.... - Fast dixon-based multisequence and multiplanar MRI for whole-body detection of cancer metastasesJingfei Ma
Department of Imaging Physics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
J Magn Reson Imaging 29:1154-62. 2009..To develop and demonstrate the feasibility of multisequence and multiplanar MRI for whole-body cancer detection...